Ilyang Pharm
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more
Ilyang Pharm (007570) - Total Liabilities
Latest total liabilities as of June 2025: ₩205.41 Billion KRW
Based on the latest financial reports, Ilyang Pharm (007570) has total liabilities worth ₩205.41 Billion KRW as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ilyang Pharm - Total Liabilities Trend (2002–2024)
This chart illustrates how Ilyang Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ilyang Pharm Competitors by Total Liabilities
The table below lists competitors of Ilyang Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
US Masters Residential Property Fund
PINK:UMRRF
|
USA | $238.88 Million |
|
Globe Trade Centre S.A.
WAR:GTC
|
Poland | zł2.01 Billion |
|
AIC Mines Limited
PINK:IAUFF
|
USA | $103.42 Million |
|
Globaltek Fabrication Co Ltd
TW:4566
|
Taiwan | NT$5.38 Billion |
|
Green Landscaping Group AB (publ)
ST:GREEN
|
Sweden | Skr4.54 Billion |
|
EuroTeleSites AG
VI:ETS
|
Austria | €1.69 Billion |
|
SCI Pharmtech Inc
TW:4119
|
Taiwan | NT$1.48 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Ilyang Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ilyang Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ilyang Pharm (2002–2024)
The table below shows the annual total liabilities of Ilyang Pharm from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩189.63 Billion | +18.33% |
| 2023-12-31 | ₩160.25 Billion | -22.33% |
| 2022-12-31 | ₩206.33 Billion | -7.27% |
| 2021-12-31 | ₩222.51 Billion | +14.58% |
| 2020-12-31 | ₩194.19 Billion | -9.56% |
| 2019-12-31 | ₩214.72 Billion | -3.44% |
| 2018-12-31 | ₩222.37 Billion | -1.34% |
| 2017-12-31 | ₩225.39 Billion | +5.37% |
| 2016-12-31 | ₩213.91 Billion | -3.04% |
| 2015-12-31 | ₩220.62 Billion | -10.81% |
| 2014-12-31 | ₩247.37 Billion | +15.32% |
| 2013-12-31 | ₩214.50 Billion | +33.50% |
| 2009-12-31 | ₩160.67 Billion | +39.31% |
| 2004-12-31 | ₩115.33 Billion | +26.51% |
| 2003-12-31 | ₩91.16 Billion | -7.51% |
| 2002-12-31 | ₩98.56 Billion | -- |